Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report

Arkadiusz Z. Dudek, Herbert Pang, Robert A. Kratzke, Gregory A. Otterson, Lydia Hodgson, Everett E. Vokes, Hedy L. Kindler

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS:: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS:: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION:: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population.

Original languageEnglish (US)
Pages (from-to)755-759
Number of pages5
JournalJournal of Thoracic Oncology
Volume7
Issue number4
DOIs
StatePublished - Apr 2012

Keywords

  • Dasatinib
  • Mesothelioma
  • SRC kinase

Fingerprint

Dive into the research topics of 'Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and leukemia group B 30601): A brief report'. Together they form a unique fingerprint.

Cite this